bioRxivPharmacology & ToxicologyPreprint
Harringtonine has the effects of double blocking SARS-CoV-2 membrane fusion
S. Hu, N. Wang, S. Chen, Q. Ding, C. Wang, W. Ma, X. ZhangiD, Y. Wu, Y. Lv, Z. Xue, H. Bai, S. Ge, H. He, W. Lu, T. Zhang, Y. Ding, R. Liu, S. Han, Y. Zhan, G. Zhan, Z. Guo, Y. Zhang, J. Lu, J. Gao, Q. Jia, , L. He
Abstract
Fusion with host cell membrane is the main mechanism of infection of SARS-CoV-2. Here, we propose a new strategy to double block SARS-CoV-2 membrane fusion by using Harringtonine (HT), a small-molecule antagonist. By using cell membrane chromatography (CMC), we found that HT specifically targeted the SARS-CoV-2 S protein and host cell TMPRSS2, and then confirmed that HT can inhibit pseudotyped virus membrane fusion. Furthermore, HT successfully blocked SARS-CoV-2 infection, especially in the delta and Omicron mutant. Since HT is a small-molecule antagonist, it is minimally affected by the continuous variation of SARS-CoV-2. Our findings show that HT is a potential small-molecule antagonist with a new mechanism of action against SARS-CoV-2 infection, and thus HT mainly targets the S protein, and thus, greatly reduces the damage of the S proteins autotoxicity to the organ system, has promising advantages in the clinical treatment of COVID-19.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein
K. Yang, C. Wang, … A. T. Brunger·bioRxiv·Aug 11, 2022
- Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
- Hemin shows antiviral activity in vitro, possibly through suppression of viral entry mediators.
M. A. UNAL, C. V. BITIRIM, … A. YILMAZER·bioRxiv·May 24, 2022
- Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects
M. Yamamoto, M. Kiso, … J.-i. Inoue·bioRxiv·Apr 22, 2020
- In silico and in vitro Demonstration of Homoharrintonine Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model